VYGR
Voyager Therapeutics Inc.
$4.67
+$0.15(+3.32%)
52
Overall
60
Value
45
Tech
--
Quality
Market Cap
$236.85M
Volume
319.10K
52W Range
$2.65 - $7.44
Target Price
$15.08
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $17.3M | $14.2M | $10.1M | $7.6M | $104.4M | $171.1M | $37.4M | $40.9M | $250.0M | $80.0M | ||
| Total Revenue | $17.3M | $14.2M | $10.1M | $7.6M | $104.4M | $171.1M | $37.4M | $40.9M | $250.0M | $80.0M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $17.3M | $14.2M | $10.1M | $7.6M | $104.4M | $171.1M | $37.4M | $40.9M | $250.0M | $80.0M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-37.6M | $-55.5M | $-82.0M | $-98.7M | $156.1M | $143.7M | $111.0M | $91.7M | $128.0M | $163.3M | ||
| Research & Development | $27.7M | $42.2M | $62.3M | $64.9M | $119.7M | $108.8M | $73.8M | $60.8M | $92.2M | $127.4M | ||
| Research Expense | $27.7M | $42.2M | $62.3M | $64.9M | $119.7M | $108.8M | $73.8M | $60.8M | $92.2M | $127.4M | ||
| Selling, General & Administrative | $9.9M | $13.3M | $19.7M | $33.8M | $36.3M | $35.0M | $37.2M | $31.0M | $35.8M | $35.9M | ||
| General & Administrative Expenses | $9.9M | $13.3M | $19.7M | $33.8M | $36.3M | $35.0M | $37.2M | $31.0M | $35.8M | $35.9M | ||
| Salaries & Wages | $-4.0M | $-6.3M | $-9.2M | $-15.7M | -- | -- | -- | $9.3M | $11.2M | $14.8M | ||
| Depreciation & Amortization | $-600.0K | $-612.0K | $-1.6M | $-2.1M | $2.8M | $3.8M | $5.2M | $6.2M | $4.4M | $4.7M | ||
| Depreciation & Amortization | $-600.0K | $-612.0K | $-1.6M | $-2.1M | $2.8M | $3.8M | $5.2M | $6.2M | $4.4M | $4.7M | ||
| Other Operating Expenses | $-37.6M | $-55.5M | $-82.0M | $-98.7M | $5.7M | $6.2M | $6.8M | $4.6M | $3.6M | $10.0M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-20.3M | $-41.3M | $-71.9M | $-91.1M | $-51.7M | $27.4M | $-73.6M | $-50.8M | $122.0M | $-83.3M | ||
| EBITDA | $-28.6M | $-38.8M | $-69.1M | $-88.5M | $-44.4M | $31.2M | $-68.5M | $-40.2M | $138.1M | $-59.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $9.8M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Intinc | $332.0K | $976.0K | $1.2M | $3.3M | $6.5M | $1.7M | $-390.0K | $1.8M | $11.7M | $18.3M | ||
| Net Non-Operating Interest Income/Expense | $332.0K | $976.0K | $1.2M | $3.3M | $6.5M | $1.7M | $-390.0K | $1.8M | $11.7M | $18.3M | ||
| Gain on Sale of Securities | $251.0K | $66.0K | $158.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $9.8M | $-182.0K | $62.0K | $683.0K | $-1.6M | $-7.7M | $-2.8M | $2.7M | $-3.0K | $-622.0K | ||
| Other Special Charges | $-9.8M | $182.0K | $-62.0K | $-683.0K | $1.6M | $7.7M | $2.8M | $2.7M | $3.0K | $622.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $2.6M | -- | -- | -- | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | $-2.6M | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $2.8M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-29.7M | $-40.1M | $-70.7M | $-88.5M | $-43.6M | $27.4M | $-73.6M | $-46.4M | $133.7M | $-64.3M | ||
| Pre-Tax Income | $-29.7M | $-40.1M | $-70.7M | $-88.5M | $-43.6M | $36.7M | $-71.2M | $-46.4M | $133.7M | $-64.3M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | $52.0K | -- | $-180.0K | -- | -- | -- | $16.0K | $1.4M | $665.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-29.7M | $-40.2M | $-70.7M | $-88.3M | $-43.6M | $36.7M | $-71.2M | $-46.4M | $132.3M | $-65.0M | ||
| Net Income (Continuing Operations) | $-29.7M | $-40.2M | $-70.7M | $-88.3M | $-43.6M | $36.7M | $-71.2M | $-46.4M | $132.3M | $-65.0M | ||
| Net Income (Discontinued Operations) | $-29.7M | $-40.2M | $-70.7M | $-88.3M | $-43.6M | $36.7M | $-71.2M | $-46.4M | $132.3M | $-65.0M | ||
| Net Income (Common Stockholders) | $-38.3M | $-40.2M | $-70.7M | $-88.3M | $-43.6M | $36.7M | $-71.2M | $-46.4M | $132.3M | $-65.0M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-60.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-37.6M | $-55.5M | $-82.0M | $-98.7M | $156.1M | $143.7M | $111.0M | $91.7M | $128.0M | $163.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $4.2M | $25.3M | $26.8M | $32.1M | $35.9M | $37.1M | $37.7M | $38.4M | $43.0M | $57.7M | ||
| Average Shares Outstanding (Diluted) | $3.2M | $25.3M | $26.8M | $32.1M | -- | $37.3M | $37.7M | $38.4M | $44.6M | $57.7M | ||
| Shares Outstanding | $26.7M | $26.8M | $32.2M | $32.6M | $37.2M | $37.7M | $38.1M | $43.3M | $54.3M | $55.2M | ||
| Basic EPS | -- | -- | -- | -- | $-1.21 | $0.99 | $-1.89 | $-1.21 | $3.08 | $-1.13 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-1.21 | $0.99 | $-1.89 | $-1.21 | $3.08 | $-1.13 | ||
| Diluted EPS | $-9.14 | $1.59 | $-2.64 | $-2.75 | $-1.21 | $0.98 | $-1.89 | $-1.21 | $2.97 | $-1.13 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $0.98 | $-1.89 | $-1.21 | $2.97 | $-1.13 | ||
| OTHER METRICS | ||||||||||||
| Accretion On Preferred Stock | $7.4M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | $1.2M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | $2.5M | -- | -- | ||
| Other Gand A | $9.9M | $13.3M | $19.7M | $33.8M | $36.3M | $35.0M | $37.2M | $31.0M | $35.8M | $35.9M | ||
| Otherunder Preferred Stock Dividend | $8.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $8.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $9.9M | $13.3M | $19.7M | $33.8M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $2.6M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VYGR | $4.67 | +3.3% | 319.10K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Voyager Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW